Evidence map›Paper›PMID 29171178›Full record

ArticleJournal of the International AIDS Society2017

HIV viral load monitoring among key populations in low- and middle-income countries: challenges and opportunities.

Sheree R Schwartz, Matthew M Kavanagh, Jeremy Sugarman, Sunil S Solomon, Illiassou M Njindam, Kevin Rebe, Thomas C Quinn, Coumba Toure-Kane, Chris Beyrer, Stefan Baral

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Negative Lifestyle Factors Specific to Aging Persons Living with HIV and Multimorbidity.Journal of the International Association of Providers of AIDS Care
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Sheree R SchwartzDepartment of Epidemiology, Center for Public Health and Human Rights, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Matthew M KavanaghCenter for Public Health Initiatives, University of Pennsylvania, Philadelphia, PA, USA.
Jeremy SugarmanBerman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
Sunil S SolomonDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Illiassou M NjindamDepartment of Epidemiology, Center for Public Health and Human Rights, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Kevin RebeAnova Health Institute, Cape Town, South Africa.
Thomas C QuinnDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Coumba Toure-KaneDepartment of Bacteriology and Virology, CHU Le Dantec, Dakar, Senegal.
Chris BeyrerDepartment of Epidemiology, Center for Public Health and Human Rights, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Stefan BaralDepartment of Epidemiology, Center for Public Health and Human Rights, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Johns Hopkins University · USAnova Health Institute · ZAHôpital Aristide Le Dantec · SNJohns Hopkins Medicine · USUniversity of Pennsylvania · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
NIAID NIH HHS P30 AI094189
6 · The paper itself

Abstract

introductionKey populations bear a disproportionate HIV burden and have substantial unmet treatment needs. Routine viral load monitoring represents the gold standard for assessing treatment response at the individual and programme levels; at the population-level, community viral load is a metric of HIV programme effectiveness and can identify "hotspots" of HIV transmission. Nevertheless, there are specific implementation and ethical challenges to effectively operationalize and meaningfully interpret viral load data at the community level among these often marginalized populations. DISCUSSION: Viral load monitoring enhances HIV treatment, and programme evaluation, and offers a better understanding of HIV surveillance and epidemic trends. Programmatically, viral load monitoring can provide data related to HIV service delivery coverage and quality, as well as inequities in treatment access and uptake. From a population perspective, community viral load data provides information on HIV transmission risk. Furthermore, viral load data can be used as an advocacy tool to demonstrate differences in service delivery and to promote allocation of resources to disproportionately affected key populations and communities with suboptimal health outcomes. However, in order to perform viral load monitoring for individual and programme benefit, health surveillance and advocacy purposes, careful consideration must be given to how such key population programmes are designed and implemented. For example, HIV risk factors, such as particular sex practices, sex work and drug use, are stigmatized or even criminalized in many contexts. Consequently, efforts must be taken so that routine viral load monitoring among marginalized populations does not cause inadvertent harm. Furthermore, given the challenges of reaching representative samples of key populations, significant attention to meaningful recruitment, decentralization of care and interpretation of results is needed. Finally, improving the interoperability of health systems through judicious use of biometrics or identifiers when confidentiality can be maintained is important to generate more valuable data to inform monitoring programmes.

conclusionsOpportunities for expanded viral load monitoring could and should benefit all those affected by HIV, including key populations. The promise of the increasing routinization of viral load monitoring as a tool to advance HIV treatment equity is great and should be prioritized and appropriately implemented within key population programmatic and research agendas.

Indexed as

Viral LoadDeveloping CountriesFemaleHIV InfectionsHumansIncomeMalePopulation SurveillanceAsiaepidemiologyHIVimplementationkey populationssub-Saharan Africasurveillanceviral load

Identifiers

PMID29171178
PMCPMC5978693
OpenAlexW2775621826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.